Advertisement

Breast Cancer Research and Treatment

, Volume 107, Issue 3, pp 427–430 | Cite as

Decline in breast cancer incidence after decrease in utilisation of hormone replacement therapy

  • Alexander Katalinic
  • Rajesh Rawal
Epidemiology

Abstract

Hormone replacement therapy (HRT) has been implicated as a risk factor for breast cancer and the use of HRT has decreased substantially in general population over the last years. Recently, there are first indications that breast cancer incidence has started declining. We examined recent breast cancer incidence and actual data on HRT utilisation in Schleswig-Holstein, Germany, to find out population based evidence on decreasing breast cancer incidence and its possible relationship with reduced HRT usage. Breast cancer incidence is taken from the population based cancer registry of Schleswig-Holstein. HRT data was extracted from a cohort of 102,000 women taking part in a quality assurance project in breast cancer diagnosis for the years 2001–2005. The annual percentage change in incidence of breast cancer and HRT utilisation was measured by linear regression. There is a linear decline in HRT utilisation among less than 50 years group, 50–69 years group and all age group women between the years 2001 and 2005. Breast cancer incidence decreased between the years 2001 and 2005 for more than 50 years old and all age group, but not in the younger than 50 years women. The decline of breast cancer incidence started about two years after the HRT decline. Breast cancer incidence decline and decreased HRT utilisation showed a high correlation. A drastic change in age-incidence relationship in breast cancer has taken place, the change is likely to continue and in future it has to be monitored closely with HRT use and other possible explanations.

Keywords

Hormone replacement therapy Germany Breast cancer incidence 

References

  1. 1.
    Anderson GL, Limacher M, Assaf AR, Bassford T, Beresford SA, Black H, Bonds D, Brunner R, Brzyski R, Caan B, Chlebowski R, Curb D et al (2004) Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women’s Health Initiative randomized controlled trial. JAMA 291(14):1701–1712PubMedCrossRefGoogle Scholar
  2. 2.
    Chlebowski RT, Hendrix SL, Langer RD, Stefanick ML, Gass M, Lane D, Rodabough RJ, Gilligan MA, Cyr MG, Thomson CA, Khandekar J, Petrovitch H et al (2003) Influence of estrogen plus progestin on breast cancer and mammography in healthy postmenopausal women: the Women’s Health Initiative Randomized Trial. JAMA 289(24):3243–3253PubMedCrossRefGoogle Scholar
  3. 3.
    Rossouw JE, Anderson GL, Prentice RL, LaCroix AZ, Kooperberg C, Stefanick ML, Jackson RD, Beresford SA, Howard BV, Johnson KC, Kotchen JM, Ockene J (2002) Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women’s Health Initiative randomized controlled trial. JAMA 288(3):321–333PubMedCrossRefGoogle Scholar
  4. 4.
    Beral V, Banks E, Reeves G (2002) Evidence from randomised trials on the long-term effects of hormone replacement therapy. Lancet 360(9337):942–944PubMedCrossRefGoogle Scholar
  5. 5.
    Beral V (2003) Breast cancer and hormone-replacement therapy in the Million Women Study. Lancet 362(9382):419–427PubMedCrossRefGoogle Scholar
  6. 6.
    Clarke CA, Glaser SL, Uratsu CS, Selby JV, Kushi LH, Herrinton LJ (2006) Recent declines in hormone therapy utilization and breast cancer incidence: clinical and population-based evidence. J Clin Oncol 24(33):e49–e50PubMedCrossRefGoogle Scholar
  7. 7.
    Ravdin PM, Cronin K, Howlander N, Chlebowski R, Berry D (2006) A sharp decrease in breast cancer incidence in the United States in 2003 Google Scholar
  8. 8.
    Dorval M, Vallee MH, Plante M, Chiquette J, Gaudet M, Simard J (2007) Effect of the Women’s Health Initiative study publication on hormone replacement therapy use among women who have undergone BRCA1/2 testing. Cancer Epidemiol Biomarkers Prev 16(1):157–160PubMedCrossRefGoogle Scholar
  9. 9.
    Kondro W. (2007) Decline in breast cancer since HRT study. CMAJ 176(2):160–161PubMedGoogle Scholar
  10. 10.
    Tormey SM, Malone CM, McDermott EW, O’Higgins NJ, Hill AD (2006) Current status of combined hormone replacement therapy in clinical practice. Clin Breast Cancer 6(Suppl 2):S51–S57PubMedCrossRefGoogle Scholar
  11. 11.
    Katalinic A, Bartel C, Raspe H, Schreer I (2007) Beyond mammography screening: quality assurance in breast cancer diagnosis (The QuaMaDi Project). Br J Cancer 96(1):157–161PubMedCrossRefGoogle Scholar
  12. 12.
    Hemminki K, Rawal R, Bermejo JL (2004) Mammographic screening is dramatically changing age-incidence data for breast cancer. J Clin Oncol 22(22):4652–4653PubMedCrossRefGoogle Scholar
  13. 13.
    Zahl PH, Strand BH, Maehlen J (2004) Incidence of breast cancer in Norway and Sweden during introduction of nationwide screening: prospective cohort study. BMJ 328(7445):921–924PubMedCrossRefGoogle Scholar
  14. 14.
    Breast cancer and hormone replacement therapy: collaborative reanalysis of data from 51 epidemiological studies of 52,705 women with breast cancer and 108,411 women without breast cancer. Collaborative Group on Hormonal Factors in Breast Cancer. Lancet (1997) 350(9084):1047–1059Google Scholar
  15. 15.
    Dietel M, Lewis MA, Shapiro S (2005) Hormone replacement therapy: pathobiological aspects of hormone-sensitive cancers in women relevant to epidemiological studies on HRT: a mini-review. Hum Reprod 20(8):2052–2060PubMedCrossRefGoogle Scholar
  16. 16.
    Tarone RE (2006) Breast cancer trends among young women in the United States. Epidemiology 17(5):588–590PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2007

Authors and Affiliations

  1. 1.Institute of Cancer EpidemiologyUniversity of LübeckLubeckGermany

Personalised recommendations